Skip to content
Bamboo Works
Search
Register / Sign in
MSCI China | MSCI China Small-Cap | Hang Seng Index | Hang Seng China Enterprise
  • Categories
    • IPO
    • Ecommerce
    • Finance
    • Social Media/Entertainment
    • Consumer
    • Education
    • Healthcare/biotech
    • New Energy
    • AI/Infrastructure/Resources
    • Property
  • Fast News
  • Expert Corner
  • Premium Content
  • China ESG
  • About
    • Who We Are
    • Our Writers
    • Partner with us
    • Contact Us
    • Join us
  • Eng
  • 简中
  • 繁中
Menu
  • Categories
    • IPO
    • Ecommerce
    • Finance
    • Social Media/Entertainment
    • Consumer
    • Education
    • Healthcare/biotech
    • New Energy
    • AI/Infrastructure/Resources
    • Property
  • Fast News
  • Expert Corner
  • Premium Content
  • China ESG
  • About
    • Who We Are
    • Our Writers
    • Partner with us
    • Contact Us
    • Join us

FDA

The innovative drug maker’s product revenue rose 82% to $747 million in the first quarter, with its star drug on pace to possibly net $2 billion for the year.

BeiGene’s aggressive expansion brings revenue jolt

The innovative drug maker’s product revenue rose 82% to $747 million in the first quarter, with its star drug on pace to possibly net $2 billion for the year Key…
May 23, 2024
BGNE.US 6160.HK 688235.SHG
This Chinese cell therapy specialist, whose core product is still in phase 1 trials, will avoid future cash flow difficulties by selling itself to the European giant.

With its sale to AstraZeneca, Gracell blazes exit trail for cash-challenged Chinese biotechs

The Chinese cell therapy specialist, whose core product is still in phase 1 trials, will avoid future cash flow difficulties by selling itself to the European giant Key Takeaways: AstraZeneca…
January 5, 2024
GRCL.US

Will Junshi Bio’s loss-making headaches ease with landmark U.S. drug approval?

The FDA has given the nod to the Chinese company’s PD-1 drug, but most of the benefits will go to a third-party licensee Key Takeaways: Junshi Bio will receive milestone…
November 9, 2023
1877.HK 688180.SHG
Biotech company Innovent Biologics announced on Thursday it recorded product revenue of more than 1.6 billion yuan in the third quarter, up 45% year-on-year.

FAST NEWS: Innovent Bio’s revenue soars on strong cancer treatment sales

The latest: Biotech company Innovent Biologics Inc. (1801.HK) announced on Thursday it recorded product revenue of more than 1.6 billion yuan ($2.2 million) in the third quarter, up 45% year-on-year, and also…
November 3, 2023
1801.HK
Cancer screening company Burning Rock Biotech announced Sunday that its OverC multi-cancer detection blood test (MCDBT) has been granted breakthrough device designation by the China National Medical Products Administration (NMPA).

FAST NEWS: Burning Rock’s cancer test gets breakthrough designation

The latest: Cancer screening company Burning Rock Biotech Ltd. (BNR.US) announced Sunday that its OverC multi-cancer detection blood test (MCDBT) has been granted breakthrough device designation by the China National…
October 17, 2023
Biotech company Innovent Biologics announced on Tuesday it will place 68 million new shares, representing approximately 4.22% of the enlarged issued share capital.

FAST NEWS: Innovent Bio to raise HK$2.4 billion in share placement

The latest: Biotech company Innovent Biologics Inc. (1801.HK) announced on Tuesday it will place 68 million new shares, representing approximately 4.22% of its enlarged share capital, to raise about HK$2.36 billion ($302 million).…
September 12, 2023
1801.HK

FAST NEWS: Luye Pharma’s Schizophrenia Drug Wins FDA Approval

The latest: Drug maker Luye Pharma Group Ltd. announced Sunday that its drug Rykindo has been approved by the U.S. Food and Drug Administration (FDA) as a treatment for schizophrenia…
January 16, 2023
Load more

Recent Articles

The innovative drug maker’s product revenue rose 82% to $747 million in the first quarter, with its star drug on pace to possibly net $2 billion for the year.
May 23, 2024

BeiGene’s aggressive expansion brings revenue jolt

BGNE.US 6160.HK 688235.SHG
January 5, 2024

With its sale to AstraZeneca, Gracell blazes exit trail for cash-challenged Chinese biotechs

GRCL.US
November 9, 2023

Will Junshi Bio’s loss-making headaches ease with landmark U.S. drug approval?

1877.HK 688180.SHG
November 3, 2023

FAST NEWS: Innovent Bio’s revenue soars on strong cancer treatment sales

1801.HK
October 17, 2023

FAST NEWS: Burning Rock’s cancer test gets breakthrough designation

September 12, 2023

FAST NEWS: Innovent Bio to raise HK$2.4 billion in share placement

1801.HK
January 16, 2023

FAST NEWS: Luye Pharma’s Schizophrenia Drug Wins FDA Approval

RELATED ARTICLES

  1. BeiGene
    January 24, 2025
    BeiGene heads for profit milestone after hemorrhaging cash
    6160.HK ONC.US 688235.SHG
  2. March 6, 2025
    Earnings blow for CSPC Pharma as the state drives a hard bargain
    1093.HK
  3. March 10, 2025
    Cango gets crypto jolt back to revenue growth, profitability
    CANG.US
  4. January 9, 2025
    Cancer drug maker Genfleet joins Hong Kong IPO influx
  5. December 5, 2024
    Xuanzhu Biopharm set for spin-off in Hong Kong IPO
    0460.HK
  6. January 13, 2025
    Blue Moon shadowed by aggressive promotional spending in slowing economy
    6993.HK
Discover hidden China stock gems in our weekly newsletter

Follow us

Facebook Twitter Linkedin Weixin Weibo Youtube

Subscribe to Our Free eNewsletter

Subscribe

Check out our content with some of our syndication partners

factiva

China stock insights and analysis for global investors: Bamboo Works unlocks investment opportunities in Chinese companies listed in the U.S. & Hong Kong.

  • About Us
  • Fast News
  • Premium Content
  • Expert Corner
  • China ESG
Facebook Twitter Linkedin Weixin Weibo Youtube

Categories

  • New Energy
  • IPO
  • Infrastructure/Resources
  • Education
  • Finance
  • Social Media/Entertainment
  • Consumer
  • Ecommerce
  • Healthcare/biotech
  • Property

Newsletter

Discover hidden China stock gems in our weekly newsletter
Copyright © 2024 Bamboo Works. All rights reserved.